Development and characterization of engineered therapeutic antibodies against SARS-CoV-2
Development and characterization of engineered therapeutic antibodies against SARS-CoV-2
批准号:
10669612
负责人:
Gaya K. Amarasinghe
金额:
$63.87万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-08-01 至 2024-07-31
关键词:
2019-nCoVACE2AddressAnimal ModelAnimalsAntibodiesAntibody TherapyBindingBiological AssayBiophysicsCOVID-19COVID-19 pandemicCessation of lifeCharacteristicsChinaChiropteraCollaborationsDevelopmentDiamondDiseaseDoseDrug CombinationsEngineeringEpitopesGeometryGlycoproteinsHealthHealthcare SystemsHumanImmunoglobulin GImmunologicsIn VitroIncidenceIncubatedIndividualInfectionInfrastructureIntegration Host FactorsLentivirusLightningLungMammalsMarketingMethodsMiddle East Respiratory Syndrome CoronavirusPersonsPhage DisplayPharmaceutical PreparationsProtein EngineeringProteinsRNA VirusesRaceReportingResearchResearch PersonnelResistanceRespiratory DiseaseSARS coronavirusSARS-CoV-2 antibodySARS-CoV-2 inhibitorSARS-CoV-2 pathogenesisSeriesSpeedSystemTechnologyTestingTherapeutic antibodiesTimeUnited StatesVaccinesValidationVesicular stomatitis Indiana virusViralVirionVirusVirus DiseasesVirus ReplicationWorkWritingantibody engineeringbetacoronavirusconvalescent plasmacurrent pandemicearly phase clinical trialexperiencein vivoindexinginnovationlead candidatemouse modelmutantneutralizing antibodypandemic diseasephysical propertypotency testingpre-clinicalreceptorreceptor bindingresistance mutationstandard of caresynergismtherapeutic candidatetransmission process
中文摘要
项目总结/文摘
英文摘要
Project Summary/Abstract
This R01 entitled, “Development and characterization of engineered therapeutic antibodies against SARS-CoV-
2”, builds on our project infrastructure, expertise, and experience in characterizing viral-host factor interactions
in negative strand RNA viruses. Since originating in China, SARS-CoV-2 has since rapidly spread and is now a
global pandemic. Significant concerns are that humans are immunologically naïve, and there are no available
therapies. In the US, the disease has already overwhelmed the healthcare system in some states and have a
serious knock-on effect in exacerbating the standard of care for other diseases. At the time of writing, nearly 5
million cases and >160,000 deaths have been attributed to COVID-19. The virus replicates in the lungs and
causes a severe respiratory disease, COVID-19, which is fatal in >2% of cases. Neutralizing antibodies (nAbs)
generated by natural infection or vaccines is known to control many infections and early studies in the current
COVID-19 pandemic, including studies to test convalescent plasma treatments, are promising. These studies
highlight the potential significance of nAb-based therapy. While IgG format of nAbs have long been the most
extensively used format, early studies, including our own suggest that additional multivalent formats of nAbs may
be more effective. This provides an innovative method to develop nAbs while acquiring potential benefits from
effective neutralization at lower doses and lower likelihood of the emergence of resistance mutants. SARS-CoV-
2 is a single stranded, non-segmented, enveloped RNA virus. Viral infection requires interaction of the spike
glycoprotein receptor binding domain (RBD) to the host receptor ACE2. Here, we will build on newly developed
and established approaches that have been optimized through our work other systems to generate antibodies
targeting spike and spike RBD using phage display technology and characterize their physical properties. We
will engineer antibodies with increased valency and test for potency in in vitro neutralization assays and in vivo
efficacy in a mouse model. At the completion, we expect to provide innovative and unique multivalent nAb leads
with unique characteristics that will rival the best in class IgG drugs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Characterizing the role of LDL related receptor 1 (Lrp1) as host entry factor for multiple bunyaviruses
-
批准号:10667857
-
项目类别:
-
资助金额:$78.36万
-
财政年份:2023
-
负责人:Gaya K. Amarasinghe
-
依托单位:
HSP90 paralog selective small molecules as anti-old-world alpha-viral therapeutic leads.
-
批准号:10753347
-
项目类别:
-
资助金额:$24.77万
-
财政年份:2023
-
负责人:Gaya K. Amarasinghe
-
依托单位:
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
-
批准号:10683329
-
项目类别:
-
资助金额:$27.21万
-
财政年份:2022
-
负责人:Gaya K. Amarasinghe
-
依托单位:
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
-
批准号:10481430
-
项目类别:
-
资助金额:$29.65万
-
财政年份:2022
-
负责人:Gaya K. Amarasinghe
-
依托单位:
Identification and Characterization of Entry Factors Critical for Rift Valley Fever Virus Infection and Pathogenesis
-
批准号:10375591
-
项目类别:
-
资助金额:$74.2万
-
财政年份:2021
-
负责人:Gaya K. Amarasinghe
-
依托单位:
Development and characterization of engineered therapeutic antibodies against SARS-CoV-2
-
批准号:10865147
-
项目类别:
-
资助金额:$38.88万
-
财政年份:2021
-
负责人:Gaya K. Amarasinghe
-
依托单位:
Development and characterization of engineered therapeutic antibodies against SARS-CoV-2
-
批准号:10458689
-
项目类别:
-
资助金额:$64.99万
-
财政年份:2021
-
负责人:Gaya K. Amarasinghe
-
依托单位:
Identification and Characterization of Entry Factors Critical for Rift Valley Fever Virus Infection and Pathogenesis
-
批准号:10573316
-
项目类别:
-
资助金额:$73.95万
-
财政年份:2021
-
负责人:Gaya K. Amarasinghe
-
依托单位:
Development and characterization of engineered therapeutic antibodies against SARS-CoV-2
-
批准号:10240126
-
项目类别:
-
资助金额:$66.73万
-
财政年份:2021
-
负责人:Gaya K. Amarasinghe
-
依托单位:
Whispering Gallery Mode Devices for the Rapid Detection of Pan-Filoviruses
-
批准号:10081794
-
项目类别:
-
资助金额:$29.99万
-
财政年份:2020
-
负责人:Gaya K. Amarasinghe
-
依托单位:
Whispering Gallery Mode Devices for the Rapid Detection of Pan-Filoviruses
-
批准号:10211125
-
项目类别:
-
资助金额:$29.18万
-
财政年份:2020
-
负责人:Gaya K. Amarasinghe
-
依托单位:
Novel VP30-host Interactions that Negatively Regulate Ebola Virus Infection
-
批准号:9765490
-
项目类别:
-
资助金额:$83.27万
-
财政年份:2019
-
负责人:Gaya K. Amarasinghe
-
依托单位:
Novel VP30-host Interactions that Negatively Regulate Ebola Virus Infection
-
批准号:9882940
-
项目类别:
-
资助金额:$79.64万
-
财政年份:2019
-
负责人:Gaya K. Amarasinghe
-
依托单位:
Novel VP30-host Interactions that Negatively Regulate Ebola Virus Infection
-
批准号:10576914
-
项目类别:
-
资助金额:$76.21万
-
财政年份:2019
-
负责人:Gaya K. Amarasinghe
-
依托单位:
Novel VP30-host Interactions that Negatively Regulate Ebola Virus Infection
-
批准号:10347335
-
项目类别:
-
资助金额:$77.43万
-
财政年份:2019
-
负责人:Gaya K. Amarasinghe
-
依托单位:
Novel VP30-host Interactions that Negatively Regulate Ebola Virus Infection
-
批准号:10721290
-
项目类别:
-
资助金额:$6.12万
-
财政年份:2019
-
负责人:Gaya K. Amarasinghe
-
依托单位:
DEVELOPMENT, VALIDATION, AND OPTIMIZATION OF HTS SCREENS TARGETING NIPAH AND HENDRA VIRUS RNA SYNTHESIS
-
批准号:9470967
-
项目类别:
-
资助金额:$53.38万
-
财政年份:2017
-
负责人:Gaya K. Amarasinghe
-
依托单位:
Molecular Mechanisms of Filoviral-host Interactions
-
批准号:10555051
-
项目类别:
-
资助金额:$335.5万
-
财政年份:2016
-
负责人:Gaya K. Amarasinghe
-
依托单位:
Structural and Functional Characterization of the Ebola Virus Replication Complex
-
批准号:9312729
-
项目类别:
-
资助金额:$274.29万
-
财政年份:2016
-
负责人:Gaya K. Amarasinghe
-
依托单位:
Administrative Core
-
批准号:10555052
-
项目类别:
-
资助金额:$27.52万
-
财政年份:2016
-
负责人:Gaya K. Amarasinghe
-
依托单位:
国内基金
海外基金
登录
查看更多内容
ACE2/AGXT2信号轴在甲基异柳磷诱导斑马鱼神经发育异常过程中的作用机制研究
-
批准号:JCZRLH202600625
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
ACE2 Ser623磷酸化调控MED1促VSMCs功能损伤在移植血管重构中的作用及机制研究
-
批准号:2026JJ50619
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:翁春艳
-
依托单位:
AURKA介导ACE2磷酸化修饰调控内皮细胞衰老在低氧性肺动脉高压中的作用及机制研究
-
批准号:82570085
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2025
-
负责人:沈慧
-
依托单位:
牛蒡叶倍半萜成分群激活ACE2/Ang1-7/MasR轴调控血管内皮—周细胞互作促缺血性脑卒中血管正常化机制研究
-
批准号:82404910
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2024
-
负责人:郝单丽
-
依托单位:
新型蝙蝠MERS簇冠状病毒HKU5的ACE2细胞受体识别及其分子机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:
-
依托单位:
ACE2通过AMPK/SIRT3调控线粒体代谢改善盐敏感性高血压肾脏纤维化的机制
-
批准号:82460087
-
项目类别:地区科学基金项目
-
资助金额:33.00万元
-
批准年份:2024
-
负责人:赵宇
-
依托单位:
铁皮石斛通过肠道 ACE2 修复 Trp/GPR142 介
导“肠-胰岛 ”轴血糖调控功能的降糖机制研
究
-
批准号:Y24H280055
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:颜美秋
-
依托单位:
人类ACE2变构抑制剂的成药性及其抗广谱冠状病毒感染的机制研究
-
批准号:82330111
-
项目类别:重点项目
-
资助金额:220万元
-
批准年份:2023
-
负责人:刘刚
-
依托单位:
CAFs来源的外泌体负性调控ACE2促进肾透明细胞癌癌栓新辅助靶向耐药的机制研究
-
批准号:82373169
-
项目类别:面上项目
-
资助金额:49万元
-
批准年份:2023
-
负责人:顾良友
-
依托单位:
新型蝙蝠MERS簇冠状病毒HKU5的ACE2受体识别及细胞入侵机制研究
-
批准号:32300137
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:陈静
-
依托单位: